<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04735770</url>
  </required_header>
  <id_info>
    <org_study_id>OuluUH/Urogyn</org_study_id>
    <nct_id>NCT04735770</nct_id>
  </id_info>
  <brief_title>LTAP Block in Endometriosis Surgery - a Randomised Controlled Double-blind Trial</brief_title>
  <official_title>Laparoscopically Inserted Transversus Abdominis Plane Block Versus Wound Local Anesthesia in Laparoscopic Endometriosis Surgery: a Prospective Randomized Controlled Double-blinded LTAP-trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oulu University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oulu University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of laparoscopically inserted&#xD;
      transversus abdominis plane block (LTAP) in comparison to local wound analgesia in&#xD;
      laparoscopic surgery due to suspected or diagnosed peritoneal endometriosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The LTAP-trial is a prospective randomized controlled double-blinded study comparing the&#xD;
      efficacy and safety of LTAP with local wound analgesia in laparoscopic endometriosis surgery.&#xD;
      Patients are randomized to receive LTAP with levobupivacain and wound infiltration with&#xD;
      placebo or wound infiltration with levobupivacain and LTAP with placebo. The primary outcome&#xD;
      is postoperative opioid consumption measured by Patient Controlled Analgesia -pump (PCA).&#xD;
      Secondly, subjective postoperative pain up to 24 h postoperatively will be measured by&#xD;
      Numeric Rating Scale (NRS). Additional outcome measures are factors related to recovery and&#xD;
      length of stay in the hospital as well as a 6 month follow-up survey regarding pain and&#xD;
      general wellbeing after surgery. A total of 46 patients will be randomized in a proportion of&#xD;
      1:1.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative opioid consumption</measure>
    <time_frame>24 hours</time_frame>
    <description>Oxicodone consumption measured via PCA-pump in Morphine equivalents</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative pain assessed by NRS (numeric rating scale)</measure>
    <time_frame>Recovery room immediately postoperatively; on ward 6, 12 and 24 hours postoperatively</time_frame>
    <description>NRS (numeric rating scale) with 0 (minimum) meaning no pain and 10 (maximum) meaning the worst imaginable pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain at six months postoperatively; assessed by NRS (numeric rating scale), (questionnaires sent to the patients)</measure>
    <time_frame>6 months postop</time_frame>
    <description>NRS (numeric rating scale) with 0 (minimum) meaning no pain and 10 (maximum) meaning the worst imaginable pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life at six months postoperatively; assessed by EHP-30 (endometriosis-related health profile) (questionnaires sent to the patients)</measure>
    <time_frame>6 months postop</time_frame>
    <description>EHP-30 (endometriosis health profile) with 0% meaning no effect on quality of life and 100% meaning maximum worsening effect on quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra- or postoperative complications</measure>
    <time_frame>Up to 6 months postop</time_frame>
    <description>Blood loss (millilitres for each participant), Reoperation (number of participants; yes/no), Hospital stay (hours/days for each participant), Readmission (number of participants for each study group), complications according to Clavien Dindo classification (Grade I meaning any deviation from the normal postoperative course; up to grade V meaning death of patient)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>Endometriosis; Peritoneum</condition>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>LTAP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive laparoscopically inserted TAP block with levobupivacain and local wound anesthesia injections with saline.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Local wound analgesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive laparoscopically inserted TAP block with saline and local wound anesthesia injections with levobupivacaine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Postoperative pain management: LTAP block or local wound anesthesia with levobupivacaine</intervention_name>
    <description>Postoperative pain management</description>
    <arm_group_label>LTAP</arm_group_label>
    <arm_group_label>Local wound analgesia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Surgery indicated because of pain caused by diagnosed or suspected peritoneal&#xD;
             endometriosis&#xD;
&#xD;
          -  ASA class 1-3&#xD;
&#xD;
          -  Patient is capable of giving informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Obstructive sleep apnea&#xD;
&#xD;
          -  ASA class &gt;4&#xD;
&#xD;
          -  Other significant risks associated with opioid use&#xD;
&#xD;
          -  Contraindications for local anesthetics or NSAIDs&#xD;
&#xD;
          -  Regular opioid consumption before operation&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sari Koivurova, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oulu University Hospital, Department of Obstetrics and Gynecology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anna M Terho, MD</last_name>
    <phone>+358405354467</phone>
    <email>anna.terho@fimnet.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oulu mUniversity Hospital</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna M Terho, MD</last_name>
      <phone>+3589405354467</phone>
      <email>anna.terho@fimnet.fi</email>
    </contact>
    <contact_backup>
      <last_name>Sari Koivurova, PhD</last_name>
      <phone>+35883153082</phone>
      <email>sari.koivurova@oulu.fi</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>January 19, 2021</study_first_submitted>
  <study_first_submitted_qc>February 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oulu University Hospital</investigator_affiliation>
    <investigator_full_name>Anna Terho</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>endometriosis</keyword>
  <keyword>postoperative pain management</keyword>
  <keyword>laparoscopic surgery</keyword>
  <keyword>gynecological surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometriosis</mesh_term>
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levobupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Anonymised data can be shared upon reasonable request to the authors.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

